Theravance (THRX) Misses Q3 EPS by 1c; Approves $150M Stock Repurchase Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Reports Third Quarter 2015 Financial Results
October 28, 2015 4:25 PM EDTSOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/28/15 -- Theravance, Inc. (NASDAQ: THRX) today reported financial results for the third quarter ended September 30, 2015. Royalties from sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA earned from Glaxo Group Limited (GSK) during the third quarter of 2015 were $16.8 million, a quarter-over-quarter increase of 21 percent compared to the second quarter of 2015. Income from operations increased to $8.4 million in the third quarter of 2015, compared to $5.1 million in the second quarter, while adjusted EBITDA for the third quarter of 2015 increased to $13.4 million compared to $10.4 million in the second quarter of... More
